Qianguo G. Mao

Xiamen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B.

A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B.

Journal: Hepatology (Baltimore, Md.)

Published: April 03, 2025

Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients.

Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients.

Journal: Microbiology spectrum

Published: April 02, 2025

Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-Suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China.

Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-Suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 19, 2025

Efficacy evaluation of extending or switching to tenofovir amibufenamide in patients with chronic hepatitis B: a phase Ⅲ randomized controlled study

Efficacy evaluation of extending or switching to tenofovir amibufenamide in patients with chronic hepatitis B: a phase Ⅲ randomized controlled study

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: November 11, 2024

Safety profile of tenofovir amibufenamide therapy extension or switching in patients with chronic hepatitis B: a phase Ⅲ multicenter, randomized controlled trial

Safety profile of tenofovir amibufenamide therapy extension or switching in patients with chronic hepatitis B: a phase Ⅲ multicenter, randomized controlled trial

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: November 11, 2024

Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B.

Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B.

Journal: Journal of viral hepatitis

Published: September 19, 2024

A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative.

A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative.

Journal: Hepatology (Baltimore, Md.)

Published: March 14, 2024

A cross-sectional survey on the types of antiviral treatment plans for patients with chronic hepatitis B

A cross-sectional survey on the types of antiviral treatment plans for patients with chronic hepatitis B

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: February 06, 2024

Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.

Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 17, 2021

Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFNα-2a in Patients with Chronic Hepatitis B and the Associated Mechanism.

Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFNα-2a in Patients with Chronic Hepatitis B and the Associated Mechanism.

Journal: Gastroenterology research and practice

Published: July 11, 2019

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a.

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a.

Journal: Journal of clinical and translational hepatology

Published: April 04, 2019

Transcriptional response of USP18 predicts treatment outcomes of interferon-alpha in HBeAg-positive chronic hepatitis B patientsefere.

Transcriptional response of USP18 predicts treatment outcomes of interferon-alpha in HBeAg-positive chronic hepatitis B patientsefere.

Journal: Journal of viral hepatitis

Published: November 30, 2018

Showing 1-12 of 18

Last Updated: 09/26/2026